Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2017 / Article
Special Issue

Interplay of Oxidative Stress, Inflammation, and Autophagy: Their Role in Tissue Injury of Heart, Liver, and Kidney

View this Special Issue

Research Article | Open Access

Volume 2017 |Article ID 6169128 | https://doi.org/10.1155/2017/6169128

Kezhen Shen, Xiaowen Feng, Hao Pan, Feng Zhang, Haiyang Xie, Shusen Zheng, "Baicalin Ameliorates Experimental Liver Cholestasis in Mice by Modulation of Oxidative Stress, Inflammation, and NRF2 Transcription Factor", Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 6169128, 11 pages, 2017. https://doi.org/10.1155/2017/6169128

Baicalin Ameliorates Experimental Liver Cholestasis in Mice by Modulation of Oxidative Stress, Inflammation, and NRF2 Transcription Factor

Academic Editor: Aditya Sen
Received25 Mar 2017
Revised18 May 2017
Accepted28 May 2017
Published05 Jul 2017


Experimental cholestatic liver fibrosis was performed by bile duct ligation (BDL) in mice, and significant liver injury was observed in 15 days. Administration of baicalin in mice significantly ameliorates liver fibrosis. Experimental cholestatic liver fibrosis was associated with induced gene expression of fibrotic markers such as collagen I, fibronectin, alpha smooth muscle actin (SMA), and connective tissue growth factor (CTGF); increased inflammatory cytokines (TNFα, MIP1α, IL1β, and MIP2); increased oxidative stress and reactive oxygen species- (ROS-) inducing enzymes (NOX2 and iNOS); dysfunctional mitochondrial electron chain complexes; and apoptotic/necrotic cell death markers (DNA fragmentation, caspase 3 activity, and PARP activity). Baicalin administration on alternate day reduced fibrosis along with profibrotic gene expression, proinflammatory cytokines, oxidative stress, and cell death whereas improving the function of mitochondrial electron transport chain. We observed baicalin enhanced NRF2 activation by nuclear translocation and induced its target genes HO-1 and GCLM, thus enhancing antioxidant defense. Interplay of oxidative stress/inflammation and NRF2 were key players for baicalin-mediated protection. Stellate cell activation is crucial for initiation of fibrosis. Baicalin alleviated stellate cell activation and modulated TIMP1, SMA, collagen 1, and fibronectin in vitro. This study indicates that baicalin might be beneficial for reducing inflammation and fibrosis in liver injury models.

1. Introduction

Chronic liver disease prevalence is increasing globally, and liver fibrosis associated with such chronic liver disease is an important cause of morbidity and mortality in the world [1]. Due to repetitive injury and inflammation in chronic liver disease, significant extracellular matrix is deposited and causes severe liver damage and organ failure. This liver fibrosis can also lead to cirrhosis and hepatocellular carcinoma [1]. Chronic cholestatic liver disease is also observed after liver transplantation [2]. Unfortunately limited antifibrotic therapies are available to treat patients with liver fibrosis [3, 4]. Many plant-derived flavonoids including baicalin show antifibrotic properties in the liver of animal models, but the mechanistic studies are limited.

The proposed mechanism of liver fibrosis includes oxidative tissue injury, mitochondrial dysregulation, and inflammation, which lead to apoptotic and necrotic cell death [5, 6]. Liver fibrogenic cells (myofibroblasts), mainly derived from hepatic stellate cells (HSC), play a central role during liver fibrosis [7]. At early stage of tissue injury, all surrounding cells to HSC contribute to its activation. Inflammation-mediated hepatocyte cell death and its engulfment by HSC result in a profibrogenic response and also activate Kupffer cells [8, 9].

Flavonoids are natural compounds and are of considerable interest in the field of drug discovery as well as food supplement industry [10]. Baicalin is one such flavonoid and derived from the roots of Scutellaria baicalensis Georgi, and these plants are mainly cultivated in China, Siberia, Russia, and Mongolia [11]. The chemical nomenclature (IUPAC) is 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl β-D-glucopyranosiduronic acid (Figure 1(a)). Protective effects of baicalin in many liver disease animal models have been reported. In a rat ischemia/reperfusion injury model, baicalin protects the liver by antioxidant and anti-inflammatory properties [12]. In concanavalin A-induced mouse liver injury, baicalin protects by modulating cytokine production [13]. Baicalin attenuates alcoholic liver injury involving sonic hedgehog pathway in addition to its antioxidant and anti-inflammatory properties [14]. In a high-fat diet-induced obesity model of mice, baicalin attenuates liver dysfunction by inhibiting CaMKK/AMPK/ACC pathway and protein kinase B/glycogen synthase kinase 3 beta pathway [15, 16]. Recently, baicalin is shown to protect the carbon tetrachloride-induced liver injury model of the rat by activating PPARγ and inhibiting TGFβ1 [17]. Here, we demonstrated the protective effect of baicalin in a cholestatic mice model was mediated via NRF2 transcription factor and its downstream target in addition to modulation of oxidative stress-generating enzymes and inflammation.

2. Materials and Methods

2.1. Mice Surgeries and Baicalin Treatment

Animal Ethics Review Committees of Zhejiang University approved the animal study protocol. Male inbred C57BL/6 (H2b) mice at 6–8 weeks old were obtained from the Animal Research Institution of Zhejiang Province (Hangzhou). BDL surgeries were performed under anesthesia as described earlier [5]. To determine the effect of baicalin on liver fibrosis, mice received one dose of preoperative (2 hours) IP injection of baicalin and alternate day postoperative IP injection of baicalin (50 mg/kg/day) for additional 14 days. For all animal experiments, we used 12 mice/group.

2.2. Liver Fibrosis Marker

Quantitative determination of liver fibrosis was performed with Picrosirius Red Stain kit (Abcam Company Ltd., China) as described earlier [5]. The quantification of collagen staining (red) was analyzed from images using ImageJ software (NIH, USA).

2.3. mRNA Quantification

RNA isolation and reverse transcription were carried out according to the previously published method [5]. Fold change was calculated as described earlier [18]. The gene-specific primers were purchased from Qiagen (USA).

2.4. Mitochondrial Electron Transport Chain Complexes

Activities of mitochondrial electron transport chain complex I, complex II, and complex IV were performed (Mitosciences, USA), and activities were expressed as fold change as described earlier [5]. Activities were determined from total tissue lysates as recommended by the manufacturer.

2.5. Liver Oxidative Stress Markers

Liver 3-NT levels were determined with ELISA kit from Hycult Biotechnology, Cell Sciences, Canton, USA, as described earlier [5].

HNE adducts were determined using the OxiSelect™ HNE Adduct ELISA Kit according to manufacturer’s instruction (Cell Biolabs, Genetimes Technology Inc., Shanghai, China) as described earlier [19].

2.6. Nuclear and Cytoplasmic Fractionation

Nuclear and cytoplasmic fractions were separated from the same set of samples by commercial kit (NE-PER Nuclear and Cytoplasmic Extraction Reagents, Thermo Fisher Scientific, USA).

2.7. Mitochondria Isolation

Mitochondria were isolated using commercial tissue mitochondria isolation kit (Pierce, USA) as described earlier [5].

2.8. Immunoblot Analyses

The protein contents were determined according to the Bradford method. Aliquots of 40 micrograms of protein were analyzed by SDS-PAGE. Western blots were carried out using antibodies for TNFα, GAPDH, NRF2, and lamin A (Abcam Company Ltd., China), Secondary antibodies were purchased from Fazendo Media (Beijing, China).

2.9. Liver PARP Activity

Liver PARP activities were determined using the commercial assay kit (Trevigen Inc.) as described earlier [5]. The quantitative values were expressed as fold change compared to those of the sham control.

2.10. Liver Apoptotic Markers

Caspase 3 activities were measured by using colorimetric caspase 3 activity assay kit (Beyotime Biotech, China) according to the manufacturer’s instruction and expressed as fold change. DNA fragment quantifications were performed with the DNA fragmentation kit (Takara, China) according to the manufacturer’s protocol.

2.11. Stellate Cell Isolation and Culture

Primary stellate cells from mice were isolated based on our earlier published method [5]. Primary stellate cells were grown for 8 days. Baicalin was added at 20 μM every day after replacing with fresh media. RNA was extracted either from fresh culture (day 0) or after 8 days (day 8), and real-time PCR was performed after reverse transcription.

2.12. Statistical Analysis

All graphical data were shown as the means ± SEMs. Multiple comparisons were performed using one-way ANOVA using Graph Pad Prism software (USA). A value less than 0.05 was considered statistically significant.

3. Results and Discussions

3.1. Baicalin Attenuates BDL-Induced Liver Fibrosis in Mice

BDL for 15 days induced significant fibrosis based on picosirius red staining, which stains collagen proteins in parenchymal cells (Figure 1(b)). Treatment with baicalin at 200 mg/kg dose on alternate day reduced fibrosis. Image quant analysis of the images demonstrated that 17.9-fold increased in fibrotic area was observed due to BDL and baicalin attenuated up to 40.3% (Figure 1(c)). In addition to fibrosis, significant increase of hepatocyte necrosis was observed and baicalin treatment attenuated those necrosis incidents (Figure 1(d)). To understand the molecular basis of fibrosis, we determined mRNA level of genes associated with fibrosis by real-time PCR. Collagen I, fibronectin, SMA, and CTGF were induced to 7.3-, 6.8-, 7.5-, and 8.3-fold, respectively, in BDL model (Figure 2). Alternate day of baicalin treatment attenuated BDL-induced mRNA of collagen I, fibronectin, SMA, and CTGF to 58%, 55%, 42%, and 65% of BDL level, respectively.

We demonstrated that baicalin protected against liver fibrosis in a well-established mice of BDL. Baicalin is the glucuronide of baicalein, which is obtained through the binding of glucuronic acid to baicalein. Baicalin has both antioxidant and anti-inflammatory properties [20, 21]. The metabolism of baicalin was studied in rodent model and no toxicity was observed [22, 23]. Liver fibrosis induced by BDL has the deposition of connective tissue elements and formation of ductular followed by necrosis [24]. Role of hepatocytes are crucial in development of liver fibrosis. Cell death of hepatocytes leads to a series of proinflammatory response [25]. Hepatocyte has complex role in liver injuries and multiple factors regulate the process including retinoic acid [26]. It is also known that biliary epithelial cells and hepatocytes can undergo epithelial–mesenchymal transition during liver fibrosis [27]. Expression of profibrotic markers such as collagen I, fibronectin, SMA and CTGF in response to BDL has been reported earlier [5, 18]. We demonstrated that all profibrotic markers were attenuated by alternate day treatment of baicalin. Consistent with our study, the protective effect of baicalin in other mouse models of liver fibrosis has been reported [28].

3.2. Baicalin Ameliorates BDL-Induced Liver Inflammation in Mice

BDL induced fibrosis, which is initiated by cell death-associated inflammatory stimuli. We determined proinflammatory cytokines TNFα, MIP1α, IL1β, and MIP2 by real-time PCR. The result demonstrated induced TNFα, MIP1α, IL1β, and MIP2 mRNA levels to 6.29-fold, 4.51-fold, 5.32-fold, and 4.83-fold, respectively (Figure 3(a)). Administration of baicalin on alternate day for 15 days reduced BDL-induced proinflammatory cytokines TNFα, MIP1α, IL1β, and MIP2 to 63%, 47%, 47%, and 49% respectively. To verify the mRNA signal to protein level, we examined one marker TNFα by immunoblot analyses and BDL increased TNFα protein level and was attenuated by baicalin, which is consistent with the mRNA expression pattern.

Our study demonstrated that baicalin prevents fibrosis by attenuating BDL-induced proinflammatory cytokines and inflammation. Modulation of inflammatory signal by baicalin in the liver for hepato-protection is well known in other liver injuries induced by concanavalin A, D-galactosamine, and alcoholic fatty liver [13, 14, 29]. The resident macrophage, known as the Kupffer cell, plays critical role in this process [30].

3.3. Baicalin Ameliorates BDL-Induced Oxidative Stress Markers in Mice

Inflammatory response in BDL induces oxidative stress and reduces cellular antioxidant capability. Here, we determined oxidative/nitrative markers and their causes. HNE protein adducts increased significantly in the liver due to BDL (3.9-fold) and baicalin treatment reduced significantly to 47% (Figure 4(a)). Hepatic protein nitration is also increased to 3.5-fold and baicalin attenuated 45.7% from BDL (Figure 4(a)). The sources of oxidative stress were investigated by real-time PCR of NOX2 and iNOS. Both of them were induced in BDL and attenuated by baicalin. Treatment with baicalin in control group does not have any effect of oxidative stress and ROS-generating sources.

BDL induced significant oxidative stress through bile salt and other free radicals which causes damage to other organs such the kidney in addition to liver [31]. In liver injury, hepatocytes are primary parenchymal cells targeted by oxidative stress [32]. Consistent with our study in BDL, the antioxidant properties of baicalin are reported in many other liver injury models [28, 33].

3.4. Baicalin Improves BDL-Impaired Mitochondrial Membrane Complex Activities in Mice

Mitochondrial electron transport chain is one of the major sources for free radical generation and oxidative injury. We examined electron transport chain complex activities from isolated mitochondria of the liver. BDL surgeries in mice reduced complex I, complex II, and complex IV activities to 45%, 35%, and 37%, respectively (Figure 5). Administration of baicalin every day during two weeks BDL improved complex I activity to 40%, complex II to 31%, and complex IV to 33%. Thus, baicalin administration significantly ameliorates BDL-induced mitochondrial dysfunction and associated oxidative injury in the liver.

Mitochondria play a bigger role in BDL-induced liver injury [34, 35]. The dysfunctional electron transport chain in mitochondria is one of the major sources of ROS [36]. We observed dysfunctional electron transport chain in BDL mouse liver, and baicalin improved those functions of electron chain complexes. Baicalin ameliorates mitochondrial damage in streptozotocin-induced diabetic rats, and its beneficial effects on mitochondria are reported [3739]. Baicalin has a beneficial effect on mitochondrial function [38].

3.5. Baicalin Enhances BDL-Induced Nuclear Translocation of Nrf2 and Increases HO-1 and GCLM Expression

NRF2 is key transcriptional regulator for antioxidant defense in many liver diseases [40]. Baicalin significantly enhanced nuclear localization of NRF2 (Figure 6(a), top panel) in BDL mice. An increase in BDL-induced NRF2 nuclear localization may be due to induction of endogenous antioxidant defense in response to oxidative stress but not sufficient to protect against injury. In addition, we also observed little increase of NRF2 in cytoplasmic fractions of BDL mice pretreated with baicalin (Figure 6(a), bottom panel). These results indicated baicalin mediated upregulation of NRF2 in fibrotic liver. Nuclear translocation of NRF2 is also associated with transcriptional activation as evident by the fact that the target genes (HO-1 and GCLM) also induced in the same pattern as nuclear translocation (Figure 6(b)).

The hepatoprotective effect of many naturally occurring compounds is mediated by NRF2 [41]. NRF2 is also is a key regulator of oxidative stress in numerous cell types [42, 43]. In BDL, Nrf2-deficient mice show reduced elimination of bile acids leading to liver injury [44]. Consistent with the key role of NRF2 in BDL, we also demonstrated that baicalin modulates NFR2 and its increased nuclear translocation led to protective effect. The induction of antioxidant defense such as HO-1 by baicalin-induced NRF2 translocation may be responsible for hepatoprotection. NRF2 translocation by baicalin is not mediated by any pro-oxidant properties, but the modulation is at the molecular level. This hypothesis is further supported by the fact that baicalin did not induce NRF2 in the control group.

3.6. Baicalin Ameliorates BDL-Induced Cell Death Pathway in Mouse Liver

BDL induces significant apoptotic and necrotic cell death in liver [5]. We examined three cell death markers DNA fragmentation, PARP activity, and caspase 3 activity. BDL induced 3.6-fold and 3.7-fold increase in apoptotic cell death markers DNA fragmentation and caspase 3 activity. Baicalin administration reduced BDL-induced DNA fragmentation and caspase 3 activity up to 40% and 42%, respectively (Figure 7(a)). We also investigated another cell death marker PARP activity which represents necrotic pathway and apoptotic pathways in liver injury [6]. BDL induced 3-fold increase in PARP activity, and baicalin administration significantly reduced BDL-induced PARP activity (44.5%) (Figure 7(b)).

Oxidative stress is major source for cell death in BDL [45, 46]. Intervention of PARP is shown to ameliorate liver fibrosis in BDL [4]. Baicalin prevented BDL-induced apoptotic and necrotic cell death. The effect may be due to reducing oxidative stress, promoting antioxidant defense, and attenuating inflammation.

3.7. Mechanistic Role of Stellate Cells in Baicalin-Mediated Antifibrotic Action

Hepatic stellate cells contribute to liver fibrosis through various steps including extracellular matrix homeostasis [47]. As we observed significant drop in liver fibrosis by baicalin, an in vitro study with stellate cells was essential. We used a natural phenomenon where spontaneous activation occurs at day 8 when stellate cells grow under in vitro condition [5]. To elucidate the inhibitory role of baicalin in the activation of stellate cell process and its effect on profibrotic marker production, we examined using real-time PCR analyses. The data demonstrated that baicalin treatment at 20 μM significantly reduced profibrotic genes such as SMA, collagen 1, and fibronectin (Figure 8).

After liver injury, stellate cell activation plays central role in initiation and propagation of liver fibrosis [48]. Kupffer cell activation facilitates stellate cell activation by secretion of TGFβ and ROS in the extracellular environment [30]. We observed modulation of stellate cell activation by baicalin in vitro. This is significant because of the fact that baicalin can modulate liver fibrosis not only by reducing oxidative stress/inflammation/cell death but also by regulating stellate cell activation.

4. Conclusion

The complexities of liver fibrosis and lack of approved treatment to patients lead this subject to forefront to researchers and clinicians. In our study, baicalin partially protects against experimental liver cholestasis via multiple mechanisms (Figure 9). The complexities of cholestatic liver fibrosis are due to the involvement of different cells in the liver such as hepatocytes, stellate cells, and immune cells, and their interactions are real crucial. Reversal of such process is challenging. Thus, the limitation of baicalin-mediated protection is due to the additional challenging factors including bioavailability, selective transportation to hepatocytes or stellate cells, or targeting other cell types. Despite the above limitations, baicalin protects against experimental cholestatic liver fibrosis by reducing inflammation, oxidative stress, and cell death and enhancing antioxidant defense in addition to modulating stellate cell activation.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Kezhen Shen and Xiaowen Feng contributed equally to this work.


This work was supported by grants from the Major Program of National Natural Science Foundation of China (no. 91542205), Science and Technology Department of Zhejiang Province (no. 2015C33214), and Zhejiang Medical and Health Science and Technology Plan Project (nos. 2014KYA070 and 200815385).


  1. Y. S. Lim and W. R. Kim, “The global impact of hepatic fibrosis and end-stage liver disease,” Clinics in Liver Disease, vol. 12, pp. 733–746, 2008, vii. View at: Publisher Site | Google Scholar
  2. T. E. Starzl, A. J. Demetris, and D. Van Thiel, “Liver transplantation (1),” The New England Journal of Medicine, vol. 321, pp. 1014–1022, 1989. View at: Publisher Site | Google Scholar
  3. M. A. Doyle, J. Singer, T. Lee, M. Muir, and C. Cooper, “Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial,” Trials, vol. 17, p. 331, 2016. View at: Google Scholar
  4. Y. Koyama, J. Xu, X. Liu, and D. A. Brenner, “New developments on the treatment of liver fibrosis,” Digestive Diseases, vol. 34, pp. 589–596, 2016. View at: Publisher Site | Google Scholar
  5. K. Shen, X. Feng, R. Su, H. Xie, L. Zhou, and S. Zheng, “Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation,” PloS One, vol. 10, article e0126278, 2015. View at: Publisher Site | Google Scholar
  6. P. Mukhopadhyay, M. Rajesh, Z. Cao et al., “Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis,” Hepatology, vol. 59, pp. 1998–2009, 2014. View at: Publisher Site | Google Scholar
  7. T. Kisseleva and D. A. Brenner, “Hepatic stellate cells and the reversal of fibrosis,” Journal of Gastroenterology and Hepatology, vol. 21, Supplement 3, pp. S84–S87, 2006. View at: Google Scholar
  8. A. Canbay, P. Taimr, N. Torok, H. Higuchi, S. Friedman, and G. J. Gores, “Apoptotic body engulfment by a human stellate cell line is profibrogenic,” Laboratory Investigation, vol. 83, pp. 655–663, 2003. View at: Publisher Site | Google Scholar
  9. A. Canbay, A. E. Feldstein, H. Higuchi et al., “Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression,” Hepatology, vol. 38, pp. 1188–1198, 2003. View at: Publisher Site | Google Scholar
  10. A. L. Harvey, R. Edrada-Ebel, and R. J. Quinn, “The re-emergence of natural products for drug discovery in the genomics era,” Nature Reviews Drug Discovery, vol. 14, pp. 111–129, 2015. View at: Publisher Site | Google Scholar
  11. D. Wozniak, E. Lamer-Zarawska, and A. Matkowski, “Antimutagenic and antiradical properties of flavones from the roots of Scutellaria baicalensis georgi,” Die Nahrung, vol. 48, pp. 9–12, 2004. View at: Publisher Site | Google Scholar
  12. S. J. Kim, Y. J. Moon, and S. M. Lee, “Protective effects of baicalin against ischemia/reperfusion injury in rat liver,” Journal of Natural Products, vol. 73, pp. 2003–2008, 2010. View at: Publisher Site | Google Scholar
  13. L. L. Liu, L. K. Gong, H. Wang et al., “Baicalin protects mouse from concanavalin A-induced liver injury through inhibition of cytokine production and hepatocyte apoptosis,” Liver International, vol. 27, pp. 582–591, 2007. View at: Publisher Site | Google Scholar
  14. H. Wang, Y. Zhang, R. Bai, M. Wang, and S. Du, “Baicalin attenuates alcoholic liver injury through modulation of hepatic oxidative stress, inflammation and sonic hedgehog pathway in rats,” Cellular Physiology and Biochemistry, vol. 39, pp. 1129–1140, 2016. View at: Publisher Site | Google Scholar
  15. Y. L. Xi, H. X. Li, C. Chen et al., “Baicalin attenuates high fat diet-induced insulin resistance and ectopic fat storage in skeletal muscle, through modulating the protein kinase B/glycogen synthase kinase 3 beta pathway,” Chinese Journal of Natural Medicines, vol. 14, pp. 48–55, 2016. View at: Google Scholar
  16. Y. Xi, M. Wu, H. Li et al., “Baicalin attenuates high fat diet-induced obesity and liver dysfunction: dose-response and potential role of CaMKKbeta/AMPK/ACC pathway,” Cellular Physiology and Biochemistry, vol. 35, pp. 2349–2359, 2015. View at: Publisher Site | Google Scholar
  17. H. Qiao, H. Han, D. Hong, Z. Ren, Y. Chen, and C. Zhou, “Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPARgamma and inhibiting TGFbeta1,” Pharmaceutical Biology, vol. 49, pp. 38–45, 2011. View at: Publisher Site | Google Scholar
  18. F. Shi, Q. Sheng, X. Xu, W. Huang, and Y. J. Kang, “Zinc supplementation suppresses the progression of bile duct ligation-induced liver fibrosis in mice,” Experimental Biology and Medicine, vol. 240, pp. 1197–1204, 2015. View at: Publisher Site | Google Scholar
  19. H. Pan, J. Chen, K. Shen et al., “Mitochondrial modulation by epigallocatechin 3-gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice,” PloS One, vol. 10, article e0124775, 2015. View at: Publisher Site | Google Scholar
  20. D. E. Shieh, L. T. Liu, and C. C. Lin, “Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin,” Anticancer Research, vol. 20, pp. 2861–2865, 2000. View at: Google Scholar
  21. B. Q. Li, T. Fu, W. H. Gong et al., “The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines,” Immunopharmacology, vol. 49, pp. 295–306, 2000. View at: Publisher Site | Google Scholar
  22. Y. Wang, J. Yang, X. Li, and J. Wang, “The metabolism of baicalin in rat and the biological activities of the metabolites,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 404529, 6 pages, 2012. View at: Publisher Site | Google Scholar
  23. M. Y. Lai, S. L. Hsiu, S. Y. Tsai, Y. C. Hou, and P. D. Chao, “Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats,” The Journal of Pharmacy and Pharmacology, vol. 55, pp. 205–209, 2003. View at: Publisher Site | Google Scholar
  24. S. Hinz, H. Franke, G. Machnik, A. Muller, and R. Dargel, “Histological and biochemical changes induced by total bile duct ligation in the rat,” Experimental and Toxicologic Pathology, vol. 49, pp. 281–288, 1997. View at: Publisher Site | Google Scholar
  25. H. Malhi, M. E. Guicciardi, and G. J. Gores, “Hepatocyte death: a clear and present danger,” Physiological Reviews, vol. 90, pp. 1165–1194, 2010. View at: Publisher Site | Google Scholar
  26. B. Mukhopadhyay, J. Liu, D. Osei-Hyiaman et al., “Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma,” The Journal of Biological Chemistry, vol. 285, pp. 19002–19011, 2010. View at: Publisher Site | Google Scholar
  27. M. D. Gorrell, “Liver fibrosis: the hepatocyte revisited,” Hepatology, vol. 46, pp. 1659–1661, 2007. View at: Publisher Site | Google Scholar
  28. S. W. Park, C. H. Lee, Y. S. Kim et al., “Protective effect of baicalin against carbon tetrachloride-induced acute hepatic injury in mice,” Journal of Pharmacological Sciences, vol. 106, pp. 136–143, 2008. View at: Publisher Site | Google Scholar
  29. L. L. Liu, L. K. Gong, H. Wang et al., “Baicalin inhibits macrophage activation by lipopolysaccharide and protects mice from endotoxin shock,” Biochemical Pharmacology, vol. 75, pp. 914–922, 2008. View at: Publisher Site | Google Scholar
  30. G. Kolios, V. Valatas, and E. Kouroumalis, “Role of Kupffer cells in the pathogenesis of liver disease,” World Journal of Gastroenterology, vol. 12, pp. 7413–7420, 2006. View at: Publisher Site | Google Scholar
  31. M. Orellana, R. Rodrigo, L. Thielemann, and V. Guajardo, “Bile duct ligation and oxidative stress in the rat: effects in liver and kidney,” Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, vol. 126, pp. 105–111, 2000. View at: Publisher Site | Google Scholar
  32. J. B. Hoek and J. G. Pastorino, “Ethanol, oxidative stress, and cytokine-induced liver cell injury,” Alcohol, vol. 27, pp. 63–68, 2002. View at: Publisher Site | Google Scholar
  33. C. C. Liao, Y. J. Day, H. C. Lee, J. T. Liou, A. H. Chou, and F. C. Liu, “Baicalin attenuates IL-17-mediated acetaminophen-induced liver injury in a mouse model,” PloS One, vol. 11, article e0166856, 2016. View at: Publisher Site | Google Scholar
  34. M. M. Tiao, T. K. Lin, P. W. Wang, J. B. Chen, and C. W. Liou, “The role of mitochondria in cholestatic liver injury,” Chang Gung Medical Journal, vol. 32, pp. 346–353, 2009. View at: Google Scholar
  35. N. Alptekin, G. Mehmetcik, M. Uysal, and G. Aykac-toker, “Evidence for oxidative stress in the hepatic mitochondria of bile duct ligated rats,” Pharmacological Research, vol. 36, pp. 243–247, 1997. View at: Publisher Site | Google Scholar
  36. K. M. Holmstrom and T. Finkel, “Cellular mechanisms and physiological consequences of redox-dependent signalling,” Nature Reviews Molecular Cell Biology, vol. 15, pp. 411–421, 2014. View at: Publisher Site | Google Scholar
  37. V. Y. Waisundara, A. Hsu, B. K. Tan, and D. Huang, “Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats,” Diabetes/Metabolism Research and Reviews, vol. 25, pp. 671–677, 2009. View at: Publisher Site | Google Scholar
  38. M. R. de Oliveira, S. F. Nabavi, S. Habtemariam, I. Erdogan Orhan, M. Daglia, and S. M. Nabavi, “The effects of baicalein and baicalin on mitochondrial function and dynamics: a review,” Pharmacological Research, vol. 100, pp. 296–308, 2015. View at: Publisher Site | Google Scholar
  39. W. H. Chang, C. H. Chen, and F. J. Lu, “Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines,” Planta Medica, vol. 68, pp. 128–132, 2002. View at: Publisher Site | Google Scholar
  40. S. M. Shin, J. H. Yang, and S. H. Ki, “Role of the Nrf2-ARE pathway in liver diseases,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 763257, 9 pages, 2013. View at: Publisher Site | Google Scholar
  41. R. N. Jadeja, K. K. Upadhyay, R. V. Devkar, and S. Khurana, “Naturally occurring Nrf2 activators: potential in treatment of liver injury,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3453926, 13 pages, 2016. View at: Publisher Site | Google Scholar
  42. H. Zhang, K. J. Davies, and H. J. Forman, “Oxidative stress response and Nrf2 signaling in aging,” Free Radical Biology & Medicine, vol. 88, pp. 314–336, 2015. View at: Publisher Site | Google Scholar
  43. O. Al-Sawaf, T. Clarner, A. Fragoulis et al., “Nrf2 in health and disease: current and future clinical implications,” Clinical Science, vol. 129, pp. 989–999, 2015. View at: Publisher Site | Google Scholar
  44. L. M. Aleksunes, A. L. Slitt, J. M. Maher et al., “Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis,” Cell Stress & Chaperones, vol. 11, pp. 356–363, 2006. View at: Publisher Site | Google Scholar
  45. F. J. Padillo, A. Cruz, C. Navarrete et al., “Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis,” Free Radical Research, vol. 38, pp. 697–704, 2004. View at: Google Scholar
  46. C. Ara, H. Kirimlioglu, A. B. Karabulut et al., “Protective effect of resveratrol against oxidative stress in cholestasis,” The Journal of Surgical Research, vol. 127, pp. 112–117, 2005. View at: Publisher Site | Google Scholar
  47. J. E. Puche, Y. Saiman, and S. L. Friedman, “Hepatic stellate cells and liver fibrosis,” Comprehensive Physiology, vol. 3, pp. 1473–1492, 2013. View at: Publisher Site | Google Scholar
  48. M. J. Arthur, D. A. Mann, and J. P. Iredale, “Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis,” Journal of Gastroenterology and Hepatology, vol. 13, pp. S33–S38, 1998. View at: Google Scholar

Copyright © 2017 Kezhen Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.